TrialLeukemia2013

Treatment outcomes in patients with relapsed and refractory multiple myeloma and high-risk cytogenetics receiving single-agent carfilzomib in the PX-171-003-A1 study.

A J Jakubowiak et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.